SCHEMBL3830185

SCHEMBL3830185

O=c1c(-c2cccnc2)c[nH]n1-c1cc(N2CC(F)(F)C2)ncn1

nearest known ligand 0.71

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 13/20 0.71
VHL P40337 7/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL13277565 0.99 P4HTM (0.70) P4HTMVHL
SCHEMBL3826774 0.86 P4HTM (0.82) P4HTMVHL
SCHEMBL8203420 0.86 P4HTM (0.82) P4HTMVHL
SCHEMBL8204028 0.85 P4HTM (0.81) P4HTMVHL
Hydrochloric Acid SCHEMBL3828062 0.85 P4HTM (0.81) P4HTMVHL
SCHEMBL8205992 0.84 P4HTM (0.80) P4HTMVHL
Hydrochloric Acid SCHEMBL3830818 0.84 P4HTM (0.79) P4HTMVHL
SCHEMBL3831641 0.84 P4HTM (0.73) P4HTMVHL
SCHEMBL8208912 0.84 P4HTM (0.75) P4HTMVHL
SCHEMBL8208131 0.83 P4HTM (1.00) P4HTMVHL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089380-B1 SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS BAYER IP GMBH (DE) 2016-06-29 EP disclosed
US-8524699-B2 Substituted dihydropyrazolones and use thereof as HIF-prolyl-4-hydroxylase inhibitors BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-09-03 US disclosed
US-8524699-B2 Substituted dihydropyrazolones and use thereof as HIF-prolyl-4-hydroxylase inhibitors BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-09-03 US disclosed
US-20120264704-A1 SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS BAYER SCHERING PHARMA AG (DE) 2012-10-18 US disclosed
US-20120264704-A1 SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS BAYER SCHERING PHARMA AG (DE) 2012-10-18 US disclosed
EP-2089380-A1 SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS Bayer Schering Pharma AG (DE) 2009-08-19 EP disclosed
WO-2008049538-A1 SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-05-02 WO disclosed
WO-2008049538-A1 SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264704-A1 SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 P4HTM 8/4885VHL 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.